Senetek terminates Invicorp license agreement with Ardana

The agreement was a license to manufacture, market, sell and distribute Invicorp in Europe and was terminated pursuant to the company’s contractual rights, precipitated by Ardana’s entry into voluntary administration on June 27, 2008.

Additionally, Senetek has also entered into an exclusive licensing and collaborative marketing agreement for the commercialization of Invicorp with Plethora Solutions for the North American market. Invicorp is a highly safe and effective treatment for erectile dysfunction.

Frank Massino, chairman and CEO of Senetek, said: “We have advised Ardana of the Invicorp license termination and served demand for return of all related clinical and regulatory data. We have received a number of inquiries regarding the availability of the European license and we are confident this will be a valuable and productive asset in the hands of the right partner.”